GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMOP.PFD) » Definitions » Long-Term Capital Lease Obligation

CDMOP.PFD (Avid Bioservices) Long-Term Capital Lease Obligation : $49.93 Mil (As of Oct. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Avid Bioservices Long-Term Capital Lease Obligation?

Avid Bioservices's Long-Term Capital Lease Obligation for the quarter that ended in Oct. 2024 was $49.93 Mil.

Avid Bioservices's quarterly Long-Term Capital Lease Obligation declined from Apr. 2024 ($51.44 Mil) to Jul. 2024 ($50.70 Mil) and declined from Jul. 2024 ($50.70 Mil) to Oct. 2024 ($49.93 Mil).

Avid Bioservices's annual Long-Term Capital Lease Obligation increased from Apr. 2022 ($39.98 Mil) to Apr. 2023 ($47.25 Mil) and increased from Apr. 2023 ($47.25 Mil) to Apr. 2024 ($51.44 Mil).


Avid Bioservices Long-Term Capital Lease Obligation Historical Data

The historical data trend for Avid Bioservices's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avid Bioservices Long-Term Capital Lease Obligation Chart

Avid Bioservices Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.24 19.89 39.98 47.25 51.44

Avid Bioservices Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.88 52.17 51.44 50.70 49.93

Avid Bioservices  (NAS:CDMOP.PFD) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Avid Bioservices Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Avid Bioservices Business Description

Industry
Traded in Other Exchanges
Address
14191 Myford Road, Tustin, CA, USA, 92780
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.